A proposed overhaul of the $100 billion federal 340B drug-discount program would shift some discounts to rebates starting January 1, 2027, so hospitals must pay upfront and wait for reimbursement. In an illustrative example, an extra $10 million balance at 6% annual interest would cost about $50,000 per month, which could increase demand for credit lines from banks that already serve hospitals. The American Hospital Association estimates administrative costs could exceed $1 billion per year, compared with HRSA's $537 million estimate for submitting claims. The article notes the incremental lending demand is unquantified, and the program faces a lawsuit filed on October 9 after an earlier rebate pilot was blocked in December 2025. Banks would benefit only if added interest exceeds funding costs and credit losses.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
healthcarebankscreditpharmaceuticals
Open a keyword to see other news on the same topic.
Related tickers and likely impact
JPM
▲ Likely positiveJPMorgan Chase
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Financials |
| Industry | Diversified Banks |
| Market cap | $891.9B |
| Close on 10/20/2026 | 335.39 |
| Change that session | +0.56% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care
NVIDIA and the UW Medicine Institute for Protein Design debuted RFD4-Proteina, an open model that combines programmable protein design with search capabilities so scientists and agents can refine designs using constraints and scoring objectives. In reported testing, it achieved higher computational design success rates and throughput than baselines across 4 benchmark suites. Siemens Healthineers is working with NVIDIA on next-generation adaptive radiotherapy using agentic co-planning, patient-specific simulation and robotic control. Automata, Benchling, Danaher and others are using the BioNeMo platform to build scientific agents that link drug design, autonomous labs and biological discovery. Projections show about 35 million people worldwide will be diagnosed with cancer each year by 2050.
- Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Alnylam shares have fallen more than 40% year to date, even though the company is now solidly profitable, with Q2 2026 GAAP net income of $164.5 million and revenue up 67% to $1.29 billion. The author attributes much of the selloff to two concerns: Alnylam cut its 2026 revenue guidance for Amvuttra and Onpattra to $4.2–4.5 billion from $4.4–4.7 billion as demand normalized after an initial surge of patients switching to Amvuttra, and disappointing Phase 3 results for Wainua in ATTR-CM raised worries about Alnylam's nucresiran. The author argues both concerns are overstated, since the two drugs use different mechanisms and Amvuttra sales continue to grow robustly. Of the 23 analysts who rated the stock over the past three months, 19 recommended buying, and the average 12-month price target implies 54% upside.
- Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
- Prime Minister: Overpriced medicines and medical equipment cause major losses for patients and the State
At a National Assembly group session on the morning of 21/10, discussing several health-sector draft laws, Prime Minister Lê Minh Hưng said medicines and medical equipment have been overpriced due to too many intermediary steps, causing major losses for patients, the state budget and the Health Insurance Fund. Inspections and investigations found many loopholes in laws, circulars and implementation, including a case involving Công ty cổ phần Đầu tư y tế Việt Mỹ, where multiple foreign companies traded goods among themselves, inflating prices and evading taxes. The government proposes urgent amendments to cut intermediaries, increase transparency, and set different procurement mechanisms: centralized bidding for common goods and direct negotiation for specialized items. The Prime Minister stressed that businesses may earn reasonable profits, but the State must control this sensitive sector.
- Amgen vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ?
This comparison pits Amgen (AMGN) against Bristol Myers Squibb (BMY), with Amgen focused on biologics and BMY strong in oncology and hematology. In FY 2025, Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion, a net margin near 21%, and free cash flow of nearly $8.1 billion. BMY generated revenue of about $48.2 billion, nearly flat, with net income of about $7.1 billion, a net margin near 14.6%, and free cash flow of about $12.8 billion. Amgen faces drug pricing pressure, an IRS tax dispute and biosimilar competition, while BMY relies heavily on Eliquis, which faces generic competition. The article describes BMY as cheaper, but says much of the difficulty appears priced in, so it is not an obvious buy right now.
Related markets
Latest news
- Tesla is trading more like SpaceX than a car company
Tesla (TSLA) has recently moved much more in step with SpaceX (SPCX): over the past 20 sessions, their correlation is 0.64, versus 0.15 in SpaceX's first 20 sessions after its June IPO. By contrast, Tesla's correlation with GM and Ford is negative, at -0.10 and -0.14. Since Elon Musk first hinted at a combination of the two companies, Tesla has risen about 4% through Tuesday, while GM and Ford have each fallen more than 11%. After removing Nasdaq 100 moves, the leftover correlation between Tesla and SpaceX is 0.32, which the article links to merger trading; SpaceX is valued at about $2.25 trillion versus about $1.52 trillion for Tesla. Options are pricing a 5.4% move after Tesla's third-quarter report, while Tesla's actual median post-earnings move since 2023 has been closer to 10% in either direction.
- The Same Banks Writing the Rules for AI Agents Are the Ones Locking Them Out
The article argues that major banks are pursuing two contradictory paths: building open standards that let AI agents access accounts while locking those agents out in practice. Bank of America and Wells Fargo appear both on the roster for the Personal Agent Protocol (Poppy), announced by Sierra and Meta, and on the list of firms restricting third-party AI access. The protocol proposes permission levels from fully blocked to full access, but payments remain outside its core specification. Meanwhile, JPMorgan Chase, Bank of America, Citi, Schwab and Wells Fargo moved to restrict third-party agents, citing concerns about rogue agents, the need for human approval of money movements, and unclear liability. The article describes this private self-regulation as filling a gap left by missing legislation.
- Treasury Secretary Bessent likens GENIUS Act to Lincoln-era banking reform
US Treasury Secretary Scott Bessent compared the GENIUS Act on stablecoins to the banking reforms under President Abraham Lincoln, calling it a “watershed moment” for American finance in an X post welcoming the Office of the Comptroller of the Currency’s (OCC) final rule. He cited the National Currency Act of 1863, and the OCC said its rule would support private-sector innovation, competition and American leadership in digital assets. The rules on stablecoin reserves, redemptions and related services take effect on January 18, 2027. From that date, companies issuing payment stablecoins in the US will generally need regulatory approval, covering national banks, federal savings associations, federal branches of foreign banks, nonbank companies and certain foreign issuers.
- Model Moats: The Vanishing Weight and the Price of the Watt
Anthropic has committed nearly $90 billion to secure compute infrastructure through Nscale, including $44.6 billion disclosed in a September SEC filing and a second deal of about $45 billion in advanced negotiations, as reported by Bloomberg; both target the Monarch Compute Campus in West Virginia. The article argues that model weights are becoming a commodity and the race has shifted to who controls power. In the same week, DeepSeek open-sourced DeepInfer and llm-d 1.0 reached general availability; IBM, citing vendor-reported figures, claims self-hosting on llm-d cuts costs 5-10x versus commercial APIs. In China, ByteDance, Alibaba and Tencent have ordered over 3 million Nvidia RTX PRO 5500 chips worth roughly $35 billion, but according to unverified social media reports, the fill rate is only 5-10%.
- A rare phenomenon just appeared on the Vietnamese stock market
Foreign investors net bought VND 190 billion on HoSE on 21/10, their second net-buying session since Vietnam was upgraded to FTSE Russell's secondary emerging market status effective 21/9, ending 20 consecutive sessions of net selling; the article notes the amount is small relative to earlier selling and a reversal cannot yet be confirmed. BSC estimates about VND 33,000 billion (USD 1.27 billion) of upgrade-related inflows next year, following a roadmap of USD 141 million in September 2026, USD 282 million in March 2027 and about USD 494 million each in June and September 2027. BSC also expects selling pressure from active funds to ease after four consecutive years of net selling, and interbank liquidity to improve as the deposit-credit gap narrowed from VND 2.8 quadrillion to VND 2.7 quadrillion in August, the first decline in 11 quarters.
- A bank stock drew buying from more than 50 funds, with Q3 profit forecast to surge
Bank stocks made up 8 of the 10 most net-bought stocks by funds in September, with net buying of about VND 1,034 billion, mainly in VPB, MBB and ACB, marking the second consecutive month of net buying. MBB drew about 52 funds, the most participants, while VPB saw net buying of 28.7 million shares from 20 funds. FiinGroup attributed much of the flow to ETF portfolio rebalancing rather than individual decisions by open-ended funds. SSI Research forecasts Q3 2026 pre-tax profit for the banks it analyzed at VND 10,000 billion, up 38% year on year but down 5% quarter on quarter, with pressure from NIM and bad debt. Meanwhile, equity funds fell an average of 6% in Q3, and investment funds saw net outflows of about VND 8,600 billion.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.